Published in Ann Oncol on October 22, 2009
ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res (2011) 1.26
ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy. J Cancer (2014) 0.90
Association between the ERCC1 rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysis. Onco Targets Ther (2015) 0.83
Molecular testing to optimize therapeutic decision making in advanced colorectal cancer. J Gastrointest Oncol (2016) 0.77
Structure of a bacterial ferredoxin. J Biol Chem (1973) 3.30
Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg (1993) 2.18
Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst (2000) 1.99
A comparison of Fe 4 S 4 clusters in high-potential iron protein and in ferredoxin. Proc Natl Acad Sci U S A (1972) 1.93
NH---S hydrogen bonds in Peptococcus aerogenes ferredoxin, Clostridium pasteurianum rubredoxin, and Chromatium high potential iron protein. Proc Natl Acad Sci U S A (1975) 1.91
Water structure in a protein crystal: rubredoxin at 1.2 A resolution. J Mol Biol (1978) 1.89
A crystallographic model for azurin a 3 A resolution. J Mol Biol (1978) 1.87
Crystallographic refinement of rubredoxin at 1 x 2 A degrees resolution. J Mol Biol (1980) 1.85
Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer (1993) 1.85
The structure of a non-heme iron protein: rubredoxin at 1.5 Angstrom resolution. Cold Spring Harb Symp Quant Biol (1972) 1.67
Crystal and molecular structure of adenosine 3',5'-cyclic phosphate. Science (1968) 1.62
Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. J Clin Oncol (1987) 1.59
A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer. Ann Oncol (2009) 1.58
Structure of rubredoxin: an x-ray study to 2.5 A resolution. J Mol Biol (1970) 1.50
Structure of the oxidized form of a flavodoxin at 2.5-Angstrom resolution: resolution of the phase ambiguity by anomalous scattering. Proc Natl Acad Sci U S A (1972) 1.47
Quality of life in Norwegian kidney donors. Nephrol Dial Transplant (1993) 1.47
Influence of solvent accessibility and intermolecular contacts on atomic mobilities in hemerythrins. Proc Natl Acad Sci U S A (1985) 1.44
[Patterns of tuberculosis manifestation in the county of Roskilde]. Ugeskr Laeger (1994) 1.41
The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol (2009) 1.40
The structure of rubredoxin at 1.2 A resolution. J Mol Biol (1979) 1.38
Structure of the Fe-S complex in a bacterial ferredoxin. Nature (1972) 1.35
Structure of Peptococcus aerogenes ferredoxin. Refinement at 2 A resolution. J Biol Chem (1976) 1.28
The binding of riboflavin-5'-phosphate in a flavoprotein: flavodoxin at 2.0-Angstrom resolution. Proc Natl Acad Sci U S A (1973) 1.26
Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer (2004) 1.23
Refinement of triclinic lysozyme: II. The method of stereochemically restrained least squares. Acta Crystallogr B (1990) 1.17
Structures of triclinic mono- and di-N-acetylglucosamine: lysozyme complexes--a crystallographic study. J Mol Biol (1976) 1.15
The prognostic importance of miR-21 in stage II colon cancer: a population-based study. Br J Cancer (2012) 1.12
Structure of rubredoxin from the bacterium Desulfovibrio desulfuricans. FEBS Lett (1986) 1.10
Microdialysis of interstitial amino acids during spreading depression and anoxic depolarization in rat neocortex. Brain Res (1993) 1.09
The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol (2010) 1.08
Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. Eur J Cancer (2006) 1.07
Granulosa cell tumor of the ovary: a population-based study of 37 women with stage I disease. Gynecol Oncol (2001) 1.07
Crystal and molecular structure of a phospholipid component: L-alpha-glycerophosphorylcholine cadmium chloride trihydrate. Science (1965) 1.06
Structure of rubredoxin from Desulfovibrio vulgaris at 1.5 A resolution. J Mol Biol (1991) 1.06
Flow cytometric classification of biopsy specimens from cervical intraepithelial neoplasia. Cytometry (1983) 1.03
Structure of ferredoxin I from Azotobacter vinelandii. Proc Natl Acad Sci U S A (1988) 1.01
Benzodiazepine receptor ligands with positive and negative efficacy. Neuropharmacology (1983) 1.00
Metal ion binding in triclinic lysozyme. J Biol Chem (1975) 1.00
Structure of methemerythrin at 2.8-Angstrom resolution: computer graphics fit of an averaged electron density map. Biochemistry (1978) 1.00
The structure of rubredoxin from Desulfovibrio desulfuricans strain 27774 at 1.5 A resolution. Proteins (1990) 1.00
Bleomycin/cis-platin as neoadjuvant chemotherapy before radical radiotherapy in localized, inoperable carcinoma of the esophagus. A prospective randomized multicentre study: the second Scandinavian trial in esophageal cancer. Radiother Oncol (1992) 0.98
Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Cancer Res (1998) 0.98
A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma. Gynecol Oncol (1987) 0.97
X-ray structural studies of ferredoxin and related electron carriers. Annu Rev Biochem (1974) 0.97
Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol Oncol (2001) 0.97
The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer. Pharmacogenomics J (2010) 0.97
A structural model of rubredoxin from Desulfovibrio vulgaris at 2 A resolution. J Mol Biol (1977) 0.96
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer. Ann Oncol (2012) 0.95
Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer. Int J Gynecol Cancer (2007) 0.95
KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer. Br J Cancer (2013) 0.94
Abecarnil, a metabolically stable, anxioselective beta-carboline acting at benzodiazepine receptors. J Pharmacol Exp Ther (1990) 0.94
Refinement of triclinic lysozyme: I. Fourier and least-squares methods. Acta Crystallogr B (1990) 0.93
A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol (1993) 0.93
Crystal structure of thiocytosine. Acta Crystallogr B (1970) 0.93
MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial. Br J Cancer (2013) 0.93
Differential pharmacological effects of benzodiazepine receptor inverse agonists. Adv Biochem Psychopharmacol (1983) 0.92
The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer. Int J Gynecol Cancer (2007) 0.91
Dopamine release in the nucleus caudatus and in the nucleus accumbens is under glutamatergic control through non-NMDA receptors: a study in freely-moving rats. Brain Res (1990) 0.91
Refined crystal structure of ferredoxin II from Desulfovibrio gigas at 1.7 A. J Mol Biol (1991) 0.91
Ultrasound elastography in patients with rectal cancer treated with chemoradiation. Eur J Radiol (2013) 0.89
The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy. Colorectal Dis (2008) 0.89
A limited sampling method for estimation of the carboplatin area under the curve. Cancer Chemother Pharmacol (1993) 0.88
Evaluation of the beta-carboline ZK 93 426 as a benzodiazepine receptor antagonist. Psychopharmacology (Berl) (1984) 0.88
Ligands for benzodiazepine receptors with positive and negative efficacy. Biochem Pharmacol (1984) 0.86
Predictive and prognostic values of cancer-associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second-look laparotomy for ovarian cancer. Gynecol Oncol (1995) 0.86
Structure of methemerythrin at 5 A resolution. J Mol Biol (1976) 0.86
DNA distribution in biopsy specimens from human cervical carcinoma investigated by flow cytometry. Virchows Arch B Cell Pathol (1979) 0.86
Contrast-enhanced ultrasound vs multidetector-computed tomography for detecting liver metastases in colorectal cancer: a prospective, blinded, patient-by-patient analysis. Colorectal Dis (2011) 0.86
The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Gynecol Oncol (2010) 0.85
Treatment of advanced bladder cancer category T2 T3 and T4a. A randomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. DAVECA protocol 8201. Danish Vesical Cancer Group. Scand J Urol Nephrol Suppl (1991) 0.85
Anticonvulsant action of the beta-carboline abecarnil: studies in rodents and baboon, Papio papio. J Pharmacol Exp Ther (1990) 0.85
MPTP-induced Parkinsonism in minipigs: A behavioral, biochemical, and histological study. Neurotoxicol Teratol (1999) 0.85
The crystal and molecular structure of the cis-syn photodimer of uracil. Acta Crystallogr B (1970) 0.85
Relation of spatial learning of rats in the Morris water maze task to the number of viable CA1 neurons following four-vessel occlusion. Behav Neurosci (1994) 0.85
Predictive value of CA 125 during early chemotherapy of advanced ovarian cancer. Gynecol Oncol (1990) 0.85
Mechanisms of renal NaCl retention in proteinuric disease. Acta Physiol (Oxf) (2013) 0.85
Tumor-associated trypsin inhibitor and cancer antigen 125 in pelvic masses. Gynecol Oncol (1990) 0.84
Aortoiliac reconstruction in preparation for renal transplantation. Transpl Int (1993) 0.84
Enantiospecific synthesis of 1-azafagomine. Chemistry (2000) 0.84
Renal transplantation in insulin-treated diabetics. Transplant Proc (1979) 0.84
The use of trout erythrocytes and human lymphocytes for standardization in flow cytometry. Cytometry (1983) 0.84
Active site structures of deoxyhemerythrin and oxyhemerythrin. Proc Natl Acad Sci U S A (1985) 0.83
Prognostic impact of ploidy level in carcinoma of the cervix. Am J Clin Oncol (1984) 0.83
CA 125 in the diagnosis of pelvic masses. Eur J Cancer Clin Oncol (1989) 0.83
Importance of HLA-DR matching in cadaveric renal transplantation: a prospective one-center study of 170 transplants. N Engl J Med (1980) 0.83
Ligands for the benzodiazepine binding site--a survey. Curr Pharm Des (1999) 0.83
Ploidy level of human breast carcinoma. Relation to histopathologic features and hormone receptor content. Acta Radiol Oncol (1984) 0.82
ZK 91296, a partial agonist at benzodiazepine receptors. Psychopharmacology (Berl) (1984) 0.82
Molecular factors of 5-fluorouracil metabolism in colorectal cancer: analysis of primary tumor and lymph node metastasis. Int J Oncol (2006) 0.82
Pharmacokinetic profiles of biphasic insulin aspart 30/70 and 70/30 in patients with Type 1 diabetes: a randomized double-blinded crossover study. Diabet Med (2005) 0.81
Proconflict effect of benzodiazepine receptor inverse agonists and other inhibitors of GABA function. Eur J Pharmacol (1984) 0.81